Department of Urology, Nara Medical University, Kashihara, Japan.
Department of Urology, Hirao Hospital, Kashihara, Japan.
BMC Res Notes. 2022 Sep 5;15(1):288. doi: 10.1186/s13104-022-06183-0.
To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil in Japanese men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with dutasteride.
Twenty-four patients were enrolled. The participants had a median age of 71.0 (64.8-73.0) years and a median prostate volume of 37.3 (29.7-41.8) mL as measured using transabdominal sonography. The efficacy indicators, such as International Prostate Symptom Score (IPSS), quality of life (QOL) score, night-time urinary frequency, and night-time maximum voided volume, improved significantly at 4 weeks, and the effects lasted until 24 weeks (IPSS: 9.5 vs. 17.0, QOL: 2.0 vs. 4.0, nocturia: 2.0 vs. 2.0, night-time maximum voided volume: 290.0 vs. 240.0 mL). Overactive bladder symptom score (OABSS) and sexual health inventory for men (SHIM) significantly improved at 12 weeks, and the effects lasted until 24 weeks (OABSS: 3.0 vs. 5.0, SHIM: 11.0 vs. 7.5). However, maximum urine flow and residual urine volume showed no improvement at any point. Adverse events occurred in two cases. Taken together, add-on therapy with tadalafil was effective for patients with LUTS/BPH resistant to dutasteride monotherapy. In addition, this therapy was not associated with severe adverse events.
评估磷酸二酯酶 5 抑制剂他达拉非作为附加疗法用于治疗多沙唑嗪治疗失败的良性前列腺增生（BPH）相关下尿路症状（LUTS）的日本男性患者的疗效和安全性。
共纳入 24 例患者。参与者的中位年龄为 71.0（64.8-73.0）岁，经腹超声测量前列腺体积中位数为 37.3（29.7-41.8）mL。疗效指标，如国际前列腺症状评分（IPSS）、生活质量（QOL）评分、夜间排尿次数和夜间最大排尿量，在 4 周时显著改善，并且效果持续到 24 周（IPSS：9.5 分比 17.0 分，QOL：2.0 分比 4.0 分，夜间排尿次数：2.0 次比 2.0 次，夜间最大排尿量：290.0 毫升比 240.0 毫升）。膀胱过度活动症症状评分（OABSS）和男性健康问卷（SHIM）在 12 周时显著改善，并且效果持续到 24 周（OABSS：3.0 分比 5.0 分，SHIM：11.0 分比 7.5 分）。然而，最大尿流率和残余尿量在任何时间点均无改善。有两例出现不良事件。总之，他达拉非附加治疗对多沙唑嗪单药治疗抵抗的 LUTS/BPH 患者有效。此外，该治疗与严重不良事件无关。
